MYC unchained: dosage-dependent locking of the myeloid fate (or not)
Experimental Hematology · 2026-07 · 159 · 105443
DOI: 10.1016/j.exphem.2026.105443 ↗Kurz gefasst
Kommentar in der Zeitschrift Experimental Hematology, 2026-07. Verfasst von Alessandro Donada. Beteiligte Einrichtung: Single Cell Initiative, Institut Curie, Paris, France. Electronic address: alessandro.donada@curie.fr. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Proto-Oncogene Proteins c-myc, Myeloid Cells, Gene Dosage. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
MYC overexpression is a crucial element of acute myeloid leukemia (AML) physiopathology. By advanced cellular modeling and molecular analysis, Stokes and colleagues showed that MYC overexpression induces a myeloid block. Sustained expression of this oncogene is required and sufficient to maintain the block, a feature shared by multiple AML subtypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Single Cell Initiative, Institut Curie, Paris, France. Electronic address: alessandro.donada@curie.fr.
Zitieren
APA
Donada, A. (2026). MYC unchained: dosage-dependent locking of the myeloid fate (or not). Experimental Hematology, 159, 105443. https://doi.org/10.1016/j.exphem.2026.105443
Vancouver
Donada A. MYC unchained: dosage-dependent locking of the myeloid fate (or not). Experimental Hematology. 2026;159:105443. doi:10.1016/j.exphem.2026.105443
BibTeX
@article{Donada2026,
author = {Donada, Alessandro},
title = {MYC unchained: dosage-dependent locking of the myeloid fate (or not)},
journal = {Experimental Hematology},
year = {2026},
volume = {159},
pages = {105443},
doi = {10.1016/j.exphem.2026.105443}
}
EUVIMED